Timothy W. Olsen
Research Subjects
Timothy W. Olsen has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
G. Baker Hubbard
Emory Eye Center, Emory University Department of Ophthalmology, and the Global Ophthalmology at Emory (GO-Emory) Program, Atlanta, Georgia
3 shared publicationsJohn F. Payne
2 shared publicationsAaron Kala
1 shared publicationAlcides Fernandes
Emory Eye Center, Emory University Department of Ophthalmology, and the Global Ophthalmology at Emory (GO-Emory) Program, Atlanta, Georgia
1 shared publicationAndrew Thliveris
1 shared publicationBhavesh Patel
Emory Eye Center, Emory University Department of Ophthalmology, and the Global Ophthalmology at Emory (GO-Emory) Program, Atlanta, Georgia
1 shared publication
Latest Publications
- 1 August 2016
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 168, 110-121
The Economic Model of Retinopathy of Prematurity (EcROP) Screening and Treatment: Mexico and the United States
- 1 August 2016
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 168, 110-121
The Economic Model of Retinopathy of Prematurity (EcROP) Screening and Treatment: Mexico and the United States
- 1 July 2015
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 56 (8) , 4976
Suprachoroidal Drug Delivery: Unique New Observations
- 1 July 2015
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 56 (8) , 4976
Suprachoroidal Drug Delivery: Unique New Observations
- 1 May 2014
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 157 (5) , 1038-1047.e1
Chorioretinal Folds: Associated Disorders and a Related Maculopathy
- 1 May 2014
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 157 (5) , 1038-1047.e1
Chorioretinal Folds: Associated Disorders and a Related Maculopathy
- 15 August 2013
- Published by Cambridge University Press (CUP)
- p. 708-710
Enucleation, evisceration, and exenteration
- 15 August 2013
- Published by Cambridge University Press (CUP)
- p. 708-710
Enucleation, evisceration, and exenteration
- 15 August 2013
- Published by Cambridge University Press (CUP)
- p. 693-695
General considerations in ophthalmic surgery
- 15 August 2013
- Published by Cambridge University Press (CUP)
- p. 693-695
General considerations in ophthalmic surgery
- 1 January 2012
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 6 (3) , 232-234
LYME DISEASE
Background: Ocular manifestations of Lyme disease are uncommon. There has not been a documented case of serous retinal detachment and chorioretinal folds because of Lyme disease that have resolved after only antibiotic treatment. Methods (Case Report): A 69-year-old white man with a history of recent tick bites presented with a gradual decrease in visual acuity in the left eye. Initial visual acuity was 3/200 in the left eye. Examination revealed an inferior, serous, macula-off retinal detachment. Chorioretinal folds were also noted. Lyme screening antibody test (enzyme-linked immunosorbent assay) was positive and a confirmatory Western blot was immunoglobulin M negative and immunoglobulin G positive. Results: Oral amoxicillin (500 mg 3 times daily for 2 weeks) was given followed by intravenous ceftriaxone (2 g daily for 4 weeks). After two weeks of ceftriaxone, fundus examination and ultrasonography showed complete reattachment of the macula and periphery, and only mild residual chorioretinal folds remained on fluorescein angiogram. Conclusion: We suggest that Borrelia burgdorferi infection led to choroidal inflammation with secondary chorioretinal folds and a serous retinal detachment, which resolved with antibiotic therapy alone. This supports the suspicion of an intraocular infection, perhaps involving the choroid, as opposed to a secondary autoimmune reaction.
- 1 January 2012
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 6 (3) , 232-234
LYME DISEASE
Background: Ocular manifestations of Lyme disease are uncommon. There has not been a documented case of serous retinal detachment and chorioretinal folds because of Lyme disease that have resolved after only antibiotic treatment. Methods (Case Report): A 69-year-old white man with a history of recent tick bites presented with a gradual decrease in visual acuity in the left eye. Initial visual acuity was 3/200 in the left eye. Examination revealed an inferior, serous, macula-off retinal detachment. Chorioretinal folds were also noted. Lyme screening antibody test (enzyme-linked immunosorbent assay) was positive and a confirmatory Western blot was immunoglobulin M negative and immunoglobulin G positive. Results: Oral amoxicillin (500 mg 3 times daily for 2 weeks) was given followed by intravenous ceftriaxone (2 g daily for 4 weeks). After two weeks of ceftriaxone, fundus examination and ultrasonography showed complete reattachment of the macula and periphery, and only mild residual chorioretinal folds remained on fluorescein angiogram. Conclusion: We suggest that Borrelia burgdorferi infection led to choroidal inflammation with secondary chorioretinal folds and a serous retinal detachment, which resolved with antibiotic therapy alone. This supports the suspicion of an intraocular infection, perhaps involving the choroid, as opposed to a secondary autoimmune reaction.
- 20 June 2011
- Published by Springer Nature
- p. 173-184
Suprachoroidal and Intrascleral Drug Delivery
- 1 June 2011
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 52 (7) , 4749-4756
Pharmacokinetics of Pars Plana Intravitreal Injections versus Microcannula Suprachoroidal Injections of Bevacizumab in a Porcine Model
Purpose.: To compare the pharmacokinetics and tissue response between intravitreal and microcannulation injections into the suprachoroidal space using bevacizumab. Methods.: Sixty-two pigs were studied. Either a pars plana intravitreal bevacizumab or a viscoelastic-enhanced microcannula suprachoroidal injection was performed with either 1.25 mg (group 1) or 3 mg (group 2). In group 1, six animals were euthanatized at 0.5, 7, 30, 60, 90, and 120 days after injection (n = 36). In group 2, six animals were euthanatized at 0.5, 7, 14, and 32 days (n = 24). Eyes were enucleated, dissected, and snap-frozen, or they were fixed for histology. Analysis of drug tissue levels was performed at two separate laboratories using masked specimens. Results.: Both laboratories were confirmatory. Intravitreal bevacizumab pharmacokinetics demonstrated a gradual decline in tissue levels over 30 to 60 days in both groups 1 and 2. In addition, suprachoroidal bevacizumab tissue levels declined rapidly and were not measurable at or beyond 7 days. Vitreitis and granulomatous vasculitis were noted in 7 of 30 intravitreal injection eyes. Immunohistology suggested a distinctive drug distribution. Conclusions.: Direct intravitreal injection of bevacizumab has a more sustained pharmacologic profile than does a similar dose delivered to the suprachoroidal space. Intravitreal injections distributed more to the inner retina, whereas suprachoroidal delivery occurred primarily at the choroid, retinal pigment epithelium, and photoreceptor outer segments. Sustained release formulation of larger biological molecules should be considered to optimize suprachoroidal delivery. Inflammation from injections is granulomatous, seen only with intravitreal injections, and may result from either an altered immune response or a dose-related effect.
- 1 June 2011
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 52 (7) , 4749-4756
Pharmacokinetics of Pars Plana Intravitreal Injections versus Microcannula Suprachoroidal Injections of Bevacizumab in a Porcine Model
Purpose.: To compare the pharmacokinetics and tissue response between intravitreal and microcannulation injections into the suprachoroidal space using bevacizumab. Methods.: Sixty-two pigs were studied. Either a pars plana intravitreal bevacizumab or a viscoelastic-enhanced microcannula suprachoroidal injection was performed with either 1.25 mg (group 1) or 3 mg (group 2). In group 1, six animals were euthanatized at 0.5, 7, 30, 60, 90, and 120 days after injection (n = 36). In group 2, six animals were euthanatized at 0.5, 7, 14, and 32 days (n = 24). Eyes were enucleated, dissected, and snap-frozen, or they were fixed for histology. Analysis of drug tissue levels was performed at two separate laboratories using masked specimens. Results.: Both laboratories were confirmatory. Intravitreal bevacizumab pharmacokinetics demonstrated a gradual decline in tissue levels over 30 to 60 days in both groups 1 and 2. In addition, suprachoroidal bevacizumab tissue levels declined rapidly and were not measurable at or beyond 7 days. Vitreitis and granulomatous vasculitis were noted in 7 of 30 intravitreal injection eyes. Immunohistology suggested a distinctive drug distribution. Conclusions.: Direct intravitreal injection of bevacizumab has a more sustained pharmacologic profile than does a similar dose delivered to the suprachoroidal space. Intravitreal injections distributed more to the inner retina, whereas suprachoroidal delivery occurred primarily at the choroid, retinal pigment epithelium, and photoreceptor outer segments. Sustained release formulation of larger biological molecules should be considered to optimize suprachoroidal delivery. Inflammation from injections is granulomatous, seen only with intravitreal injections, and may result from either an altered immune response or a dose-related effect.
- Open Access
- 1 December 2010
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 128 (12) , 1546-1550
Concentrated Intravitreal Amphotericin B in Fungal Endophthalmitis
Research from JAMA Ophthalmology — Concentrated Intravitreal Amphotericin B in Fungal Endophthalmitis
- 1 December 2010
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 128 (12) , 1546-1550
Open AccessConcentrated Intravitreal Amphotericin B in Fungal Endophthalmitis
Research from JAMA Ophthalmology — Concentrated Intravitreal Amphotericin B in Fungal Endophthalmitis
- 1 October 2009
- Published by Elsevier in Experimental Eye Research
- Vol. 89 (4) , 456-461
Ex vivo porcine iris stiffening due to drug stimulation
- 1 October 2009
- Published by Elsevier in Experimental Eye Research
- Vol. 89 (4) , 456-461
Ex vivo porcine iris stiffening due to drug stimulation